Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | DAO | P14920 | 1/20 | 0.40 |
| ▸ | TNKS | O95271 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10153919 | 0.80 | DAO (0.38) | CHRM3DAOHPGD | |
| SCHEMBL19187342 | 0.78 | DAO (0.37) | CHRM3DAO | |
| SCHEMBL24724927 | 0.76 | DAO (0.35) | CHRM3DAO | |
| SCHEMBL9414397 | 0.76 | TYR (0.30) | — | |
| SCHEMBL131245 | 0.76 | MLYCD (0.43) | CHRM3DAOMAPK1 | |
| SCHEMBL12615412 | 0.74 | ALDH1A1 (0.32) | HPGD | |
| SCHEMBL20933012 | 0.74 | MAPK14 (0.32) | — | |
| SCHEMBL129652 | 0.74 | — | — | |
| SCHEMBL128214 | 0.74 | DAO (0.48) | CHRM3DAOHPGDMAPK1 | |
| SCHEMBL127047 | 0.73 | DAO (0.37) | CHRM3DAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-16 | — | — | US | disclosed |
| US-10857123-B2 | NLRP3 inhibitors for the treatment of inflammatory skin disorders | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2020-12-08 | — | — | US | disclosed |
| WO-2020102576-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-22 | — | — | WO | disclosed |
| US-10654816-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-19 | — | — | US | disclosed |
| EP-3407877-B1 | NLRP3 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY SKIN DISORDERS | GALDERMA RES & DEV (FR) | 2020-03-04 | — | — | EP | disclosed |
| US-20190192478-A1 | NLRP3 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY SKIN DISORDERS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2019-06-27 | — | — | US | disclosed |
| WO-2019023147-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | IFM Tre, Inc. (US) | 2019-01-31 | — | — | WO | disclosed |
| WO-2017129897-A1 | NLRP3 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY SKIN DISORDERS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2017-08-03 | — | — | WO | disclosed |
| US-8450319-B2 | Pyrrolopyridazinone compound | UBE INDUSTRIES, LTD. (JP) | 2013-05-28 | — | — | US | disclosed |
| EP-1982986-B1 | PYRROLOPYRIDAZINONE COMPOUND AS PDE4 INHIBITOR | UBE INDUSTRIES (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20090036453-A1 | Pyrrolopyridazinone Compound | UBE INDUSTRIES, LTD. (JP) | 2009-02-05 | — | — | US | disclosed |
| EP-1982986-A1 | PYRROLOPYRIDAZINONE COMPOUND | Ube Industries, Ltd. (JP) | 2008-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | CHRM3 4211/4885DAO 3826/4885TNKS 458/4885 |
| US-10857123-B2 | NLRP3 inhibitors for the treatment of inflammatory skin disorders | NLRP3, NLRP1, PYCARD | CHRM3 4816/4885DAO 2609/4885TNKS 807/4885 |
| US-10654816-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NLRP1, NLRP3, NOD1 | CHRM3 4043/4885DAO 3886/4885TNKS 556/4885 |
| US-20190192478-A1 | NLRP3 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY SKIN DISORDERS | NLRP3, NLRP1, PYCARD | CHRM3 4816/4885DAO 2609/4885TNKS 807/4885 |
| US-20090036453-A1 | Pyrrolopyridazinone Compound | CBR3, CBR1, CYC1 | CHRM3 182/4885DAO 388/4885TNKS 3051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.